Open-label, single-arm, multicenter confirmatory phase 2 study of the bite® antibody blinatumomab in patients with relapsed/refractory b-precursor acute lymphoblastic leukaemia

Authors
Category Primary study
JournalHaematologica
Year 2014
This article has no abstract
Epistemonikos ID: 51145c8c194cbdc643f209b06d865d42c5ac358f
First added on: Feb 06, 2025